Shandong Tefaman Pharmaceutical

Shandong Tefaman Pharmaceutical is a Chinese pharmaceutical enterprise focused on the development and production of high-end generic drugs and active pharmaceutical ingredients (APIs). Established in 2018 and headquartered in Heze, Shandong, the company specializes in therapeutic areas including cardiovascular health, metabolic diseases, and oncology. Its commercial portfolio features widely used anticoagulants such as rivaroxaban and apixaban, as well as anti-diabetic agents like sitagliptin and empagliflozin. Tefaman maintains large-scale manufacturing capabilities designed to meet global regulatory standards, positioning itself as a key supplier in the chemical drug industry. The company integrates research, development, and production to provide cost-effective therapeutic solutions for chronic diseases.